AI in Regulatory Affairs Market Size, Share & Trends Analysis Report By Component (Software/Platform, Services), By Deployment Mode (Cloud-based, On-Premises), By Application (Regulatory Intelligence, Data Migration & Integration, Dossier Management, Document Management, Product Registration & Approvals, Pharmacovigilance & Safety Reporting, Regulatory Submissions & Publishing, Others), By End Use (Pharmaceutical Companies, Biotechnology Companies, Medical Device Companies, CRO/CDMO, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

AI in Regulatory Affairs Market Size

The global AI in regulatory affairs market size was valued at USD 1.54 billion in 2025 and is projected to grow from USD 1.83 billion in 2026 to USD 7.18 billion by 2034, registering a CAGR of 18.66% during the forecast period from 2026 to 2034. North America dominated the AI in regulatory affairs market with a market share of 37.68% in 2025.

Component Insights

The software platform segment dominated the AI in regulatory affairs market in 2025, driven by extensive adoption of AI-based regulatory intelligence systems, submission management platforms, and document automation tools across life sciences organizations. Increasing regulatory complexity and rising volumes of structured and unstructured regulatory data continue to support sustained deployment of integrated software platforms across regulatory workflows.

The services segment is projected to record a CAGR of 19.83% in the AI in regulatory affairs market, supported by growing demand for AI-enabled regulatory operations, platform implementation, system integration, and ongoing regulatory support services.

Request Customizationto receive a tailored report.

Deployment Mode Insights

The cloud-based segment dominated the AI in regulatory affairs market in 2025. This segment enhances the deployment experience due to reliance on centralized data management platforms. It has scalability features, which can be integrated across enterprises without compromising on geographical expanse. It also supports changing regulatory updates and cross-functional collaborations within global regulatory operations.

The on-premises segment is anticipated to grow at 19.99% due to the need for organizational data governance policies in the AI in regulatory affairs market. The preference for internal control over sensitive regulatory information is growing. On-premises deployment offers full control over data storage and access. This reduces third-party cloud breaches and vendor misuse of sensitive regulatory IP. It also helps demonstrate compliance during audits and avoid legal ambiguity in case of changing regulations and monitoring of datasets.

Application Insights

The regulatory intelligence segment held a 20.14% share in the AI in regulatory affairs market in 2025. The segment growth is supported by increasing use of AI for monitoring regulatory changes, tracking authority guidelines, and assessing regulatory impact across product portfolios. Continuous regulatory updates and jurisdiction-specific requirements sustain the adoption of AI-driven regulatory intelligence tools.

The pharmacovigilance and safety reporting segment is expected to grow at 19.65% in the AI in regulatory affairs market. It is driven by rising adverse event reporting volumes and increasing use of AI for safety case processing and compliance reporting. Pharmacovigilance encompasses the monitoring of huge volumes of electronic health records and adverse drug reaction reports. AI identifies safety gaps, detects long-term safety trends, and flags potential risks, which can lead to quicker interventions to safeguard compliance requirements.

End Use Insights

Pharmaceutical companies dominated the AI in regulatory affairs market in 2025 with a share of 40.45%. Pharmaceutical companies have high submission volumes and need to adhere to complex approvals. They need assistance in document extraction, validation, dossier preparation, and formatting. They also operate under pressure to accelerate clinical drug development and clinical trials, considering optimal regulatory pathways. Larger companies are using AI models not only for document submissions but also for real-world evidence monitoring, safety surveillance, and trial data systems. They also need to focus on continuous post-approval compliance requirements across global markets. AI-based regulatory platforms support structured dossier preparation and lifecycle tracking.

The CRO and CDMO segment is projected to register the fastest growth in the AI in regulatory affairs market, with a share of 19.25%. This segment is driven by increased outsourcing of regulatory activities and growing reliance on AI-enabled systems to manage multi-client regulatory operations efficiently. CROs and CDMOs are using AI to improve clinical trial workflows, optimize manufacturing processes, and enhance real-time reporting. They are also updating their offerings with the integration of AI to improve enhanced data management and faster regulatory intelligence.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The AI in regulatory affairs market in North America dominated the market with a share of 37.68%. The region is an early adopter of digital regulatory platforms and advanced regulatory infrastructure across pharmaceutical, biotechnology, and medical device companies. It has an established electronic submission system and structured regulatory pathways. This supports the integration of AI-based tools across regulatory intelligence, submission lifecycle management, and compliance monitoring workflows.

The US accounted for the largest regional share, which is driven by a high volume of regulatory workloads and sustained investments in automation. The country already has higher willingness to adopt AI-driven systems, which is an added advantage in a robust healthcare infrastructure. In June 2025, the US Food and Drug Administration announced the internal deployment of a generative AI system named Elsa to support scientific review activities, document summarization, and regulatory data analysis, as disclosed on the official FDA website.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific

The Asia Pacific AI in regulatory affairs market is expected to register a CAGR of 20.66% during the forecast period. The region is by large-scale digitization initiatives and increasing regulatory complexity across the pharmaceutical and medical device sectors. Countries across the region are investing in electronic regulatory systems to manage growing submission volumes and cross-border compliance requirements.

In China, government-led regulatory modernization programs and centralized digital submission platforms continue to accelerate adoption of AI-based regulatory tools across domestic and multinational life sciences organizations. For example, the National Medical Products Administration (NMPA) introduced AI-specific regulatory guidance and review frameworks for artificial intelligence medical devices. This enables the use of AI-driven tools for dossier validation, technical review support, and post-approval performance monitoring.

Europe

Europe has a harmonized regulatory framework and regional policies that encourage the digital transformation of regulatory processes. A unified electronic submission standard across the EU supports broader use of AI-driven systems. Regulatory agencies such as MHRA in the UK and BfArM in Germany are advancing AI integration for better assessment and evaluation of the review process. The region has mature pharmaceutical, biotech, and MedTech industries, which drive demand for AI review systems. The region also has initiatives that encourage and integrate AI innovation and adoption. For instance, InvestAI mobilizes extensive public and private capital to boost AI adoption. All these factors are expected to boost steady growth in the European AI in regulatory affairs market.

Germany has implemented digital health and regulatory modernization initiatives. The National Research Data Infrastructure links data across multiple domains for health research and regulatory purposes. Mission KI connects stakeholders such as startups, SMEs, and research institutes for the commercial deployment of AI. Companies in this country are increasingly deploying AI-driven regulatory intelligence and submission management systems to align with European Medicines Agency requirements. This helps to automate dossier preparation and accelerate cross-border regulatory approvals.

Latin America

Latin America demonstrates steady growth in the AI in regulatory affairs market with the onset of regulatory digitization and expansion of electronic submission infrastructure. National regulatory agencies are strengthening digital review systems and standardized regulatory workflows, improving readiness for AI-based regulatory tools. For instance, COFEPRIS (Mexico) aligns regulatory submissions as per global standards. The region has an evolving health-tech and digital innovation ecosystem, promoting companies to leverage AI for healthcare.

Brazil leads the region through public sector investments in regulatory information systems and structured electronic submission frameworks. For example, the Agência Nacional de Vigilância Sanitária (ANVISA) has established a comprehensive electronic petitioning and submission platform that enables regulated companies to file regulatory requests, applications and structured electronic dossiers (e-submissions) directly with the agency through its Solicita and Peticionamento electronic systems, modernizing review workflows and improving transparency and traceability of regulatory interactions.

Middle East and Africa

The Middle East and Africa market is progressing due to the modernization efforts toward digital health infrastructure. The region is also encouraging AI adoption through public sector initiatives. For instance, the Vision 2030 initiative by Saudi Arabia promotes the use of AI in the healthcare sector for predictive analysis. This is giving an economic push toward digital compliance tools. Clinical trial activities are also growing in the GCC countries. Thus, this will lead to growing demand for testing and submission tools in the Middle East and Africa AI in regulatory affairs market.

South Africa holds a leading position in the region due to regulatory system modernization and widespread deployment of electronic regulatory workflows across public and private sector life sciences organizations. The South African Health Products Regulatory Authority (SAHPRA) has implemented an eCTD electronic submission portal as the preferred platform for registering human medicines, variations, and renewals. This enables sponsors to submit structured dossiers digitally in accordance with international standards, enhancing review efficiency and traceability across the product lifecycle.

Competitive Landscape

The AI in regulatory affairs market is moderately fragmented, with a mix of established software providers and emerging vendors. Leading players and other specialized regulatory technology firms dominate the market. They offer advanced AI-enabled platforms that have deep domain expertise and an easier integration with quality and clinical systems. Companies focus on product innovations, strategic partnerships with life sciences organizations, and platform scalability to strengthen their market presence. They compete on factors such as regulatory compliance accuracy, automation, interoperability, regulatory intelligence, workflow customization, deployment flexibility, and data security.

List of Key and Emerging Players in AI in Regulatory Affairs Market